PubMed:27785115 JSONTXT

{"project":"maxiaofeng52_800_3","denotations":[{"id":"T1","span":{"begin":56,"end":66},"obj":"CI"},{"id":"T2","span":{"begin":486,"end":496},"obj":"CI"},{"id":"T3","span":{"begin":1047,"end":1057},"obj":"CI"},{"id":"T4","span":{"begin":1933,"end":1943},"obj":"CI"},{"id":"T5","span":{"begin":266,"end":276},"obj":"CI"},{"id":"T6","span":{"begin":214,"end":223},"obj":"DP"},{"id":"T7","span":{"begin":375,"end":384},"obj":"DP"},{"id":"T8","span":{"begin":969,"end":978},"obj":"DP"}],"text":"Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.\nBACKGROUND: Most biologic therapies for psoriasis are delivered via subcutaneous injection. Ixekizumab, an anti-interleukin 17A monoclonal antibody approved for patients with moderate-to-severe plaque psoriasis, is delivered subcutaneously via prefilled syringe or autoinjector. Here we report the results of an ixekizumab autoinjector usability study as well as the patient-reported experience with the autoinjector in a clinical trial.\nMETHODS: The usability study enrolled 49 subjects (patients with a range of autoimmune conditions or their caregivers). Subjects were randomized to a trained or untrained group and were evaluated for their ability to perform an injection successfully when provided the device and the instructions for use. In the clinical trial, 102 subjects (patients with psoriasis or their caregivers) used the autoinjector to deliver injections of ixekizumab (80 mg every 2 weeks after a starting dose of 160 mg). At weeks 0, 4, and 8, subjects completed the subcutaneous administration assessment questionnaire, which assesses the ease of use and confidence with using an injection device.\nRESULTS: In the usability study, all subjects in the untrained arm performed successful injections, while two subjects in the trained arm had an injection failure. These incidences were not consistent with any pattern of issues with the device or the instructions for use. In the clinical trial, there were two injection failures of 674 total self-injections performed over 12 weeks. At the first use of the device, 95% of subjects either agreed or strongly agreed that the device was \"overall easy to use\", and they felt \"confident the dose was complete\" according to the subcutaneous administration assessment questionnaire.\nCONCLUSION: The ixekizumab autoinjector was used successfully by patients and caregivers with or without training. Subjects using the autoinjector in a clinical trial felt it was easy to use and felt confident while using it."}

{"project":"wangzhuo19_800_3","denotations":[{"id":"T1","span":{"begin":969,"end":978},"obj":"DP"},{"id":"T2","span":{"begin":214,"end":223},"obj":"DP"},{"id":"T3","span":{"begin":375,"end":384},"obj":"DP"},{"id":"T4","span":{"begin":266,"end":276},"obj":"CI"},{"id":"T5","span":{"begin":56,"end":66},"obj":"CI"},{"id":"T6","span":{"begin":486,"end":496},"obj":"CI"},{"id":"T7","span":{"begin":1047,"end":1057},"obj":"CI"},{"id":"T8","span":{"begin":1933,"end":1943},"obj":"CI"}],"text":"Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.\nBACKGROUND: Most biologic therapies for psoriasis are delivered via subcutaneous injection. Ixekizumab, an anti-interleukin 17A monoclonal antibody approved for patients with moderate-to-severe plaque psoriasis, is delivered subcutaneously via prefilled syringe or autoinjector. Here we report the results of an ixekizumab autoinjector usability study as well as the patient-reported experience with the autoinjector in a clinical trial.\nMETHODS: The usability study enrolled 49 subjects (patients with a range of autoimmune conditions or their caregivers). Subjects were randomized to a trained or untrained group and were evaluated for their ability to perform an injection successfully when provided the device and the instructions for use. In the clinical trial, 102 subjects (patients with psoriasis or their caregivers) used the autoinjector to deliver injections of ixekizumab (80 mg every 2 weeks after a starting dose of 160 mg). At weeks 0, 4, and 8, subjects completed the subcutaneous administration assessment questionnaire, which assesses the ease of use and confidence with using an injection device.\nRESULTS: In the usability study, all subjects in the untrained arm performed successful injections, while two subjects in the trained arm had an injection failure. These incidences were not consistent with any pattern of issues with the device or the instructions for use. In the clinical trial, there were two injection failures of 674 total self-injections performed over 12 weeks. At the first use of the device, 95% of subjects either agreed or strongly agreed that the device was \"overall easy to use\", and they felt \"confident the dose was complete\" according to the subcutaneous administration assessment questionnaire.\nCONCLUSION: The ixekizumab autoinjector was used successfully by patients and caregivers with or without training. Subjects using the autoinjector in a clinical trial felt it was easy to use and felt confident while using it."}